Healthy VolunteersPhase 1NCT07818967
A Study of Abemaciclib (LY2835219) in Healthy Participants
A Phase 1 study testing Abemaciclib Tablet (Test Formulation), Abemaciclib Tablet (Reference Formulation) and Abemaciclib Oral Granules (Test Formulation) in people with Healthy Volunteers, run by Eli Lilly and Company at 1 site in Singapore.
Trial summary
The main purpose of this study is to compare different forms of abemaciclib (LY2835219) to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. Read more about this study
- Who is it for?
- Ages 21 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers
- What is being tested?
- Abemaciclib Tablet (Test Formulation), Abemaciclib Tablet (Reference Formulation) and Abemaciclib Oral Granules (Test Formulation)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteSingapore
- Study dates
- 2 Sep 2026to Nov 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Have a body mass index (BMI) within the range of 18 to 32 kilograms per square meter (kg/m²), inclusive, and have a body weight of 45 kilograms (kg) or greater.
- Individuals assigned male at birth (AMAB) should be sterile, including vasectomy.
- Individuals who are assigned female at birth (AFAB) and are individuals not of childbearing potential (INOCBP).
- Have clinical laboratory test results within normal reference range for the population or investigative site.
- Have a hemoglobin level of 12.5 grams per deciliter (g/dL) or greater for males, or 11.4 g/dL for females.
- Have venous access sufficient to allow for blood sampling.
Who cannot join
- Have known allergies to abemaciclib, related compounds, or any components of the formulations, or have a history of significant atopy.
- Have a 12-lead electrocardiogram (ECG) abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
- Have abnormal blood pressure as determined by the investigator.
- Have a gastrointestinal disorder causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes.
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders that could significantly alter the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study medication, or of interfering with the interpretation of study data.
- Have known or ongoing psychiatric disorders.
Show all 19Show fewer
- Have used or intend to use over the counter or prescription medication, or herbal supplements, within 14 days prior to the first dose. The use of topical medicine, provided there is no evidence of chronic dosing with risk of systemic exposure, and occasional acetaminophen is acceptable.
- Use or intend to use any medications or products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 14 days prior to Study Day 1, unless deemed acceptable by the investigator or designee.
- Use or intend to use medications that are moderate or strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4), including cannabidiol- or cannabis-containing products, within 14 days prior to Study Day 1 until completion of the follow-up phone call.
- Regularly use known drugs of abuse.
- Show evidence of Human Immunodeficiency Virus (HIV) infection or positive HIV antibodies.
- Have a positive Hepatitis C Virus (HCV) antibody test. Participants with a positive HCV antibody test at screening can be included only if a confirmatory HCV Ribonucleic Acid (RNA) test is negative.
- Show evidence of hepatitis B or positive hepatitis B surface antigen.
- Have made a blood donation of 450 milliliters (mL) or greater, or have participated in a clinical study that required a blood volume of 400 mL or more since the last study visit, within the last 3 calendar months.
- Are unwilling to refrain from strenuous exercise for at least 72 hours prior to each dose and during each inpatient stay.
- Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation, or an amount deemed significant by the investigator, or are unwilling to stop alcohol consumption for at least 48 hours prior to each Clinical Research Unit (CRU) admission until discharge from the CRU in each treatment period.
- Are unwilling to refrain from consuming caffeine- or xanthine- containing products from at least 48 hours prior to each CRU admission until discharge from the CRU in each treatment period.
- Are currently, or have been, smokers or users of tobacco or nicotine replacement products within the 6 months prior to the first CRU admission, or have a positive cotinine test at screening.
- Are unwilling to comply with the dietary requirements and restrictions of this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Singapore1 site, 1 recruiting
- Recruiting
Lilly Centre for Clinical Pharmacology
Singapore, 138623
About this study
Official title: A Phase 1, Open-Label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Abemaciclib (LY2835219) Test and Reference Formulations and an Alternate Administration Method, in Healthy Participants.
The main purpose of this study is to compare different forms of abemaciclib (LY2835219) to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 12 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 10 days.
- Conditions
- Healthy Volunteers
- Being tested
- Abemaciclib Tablet (Test Formulation), Abemaciclib Tablet (Reference Formulation), Abemaciclib Oral Granules (Test Formulation)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Abemaciclib Tablet (Test Formulation)Drug
Administered orally as a tablet in one of three treatment periods.
Abemaciclib Tablet (Reference Formulation)Drug
Administered orally as a tablet in one of three treatment periods.
Abemaciclib Oral Granules (Test Formulation)Drug
Administered orally in one of three treatment periods.
| Study group | Role | What they receive |
|---|---|---|
| Abemaciclib (Test Formulation 1) | Experimental | Administered orally in one of three treatment periods. Receives: Drug: Abemaciclib Tablet (Test Formulation) |
| Abemaciclib (Test Formulation 2) | Experimental | Administered orally in one of three treatment periods. Receives: Drug: Abemaciclib Oral Granules (Test Formulation) |
| Abemaciclib (Reference Formulation 1) | Experimental | Administered orally in one of three treatment periods. Receives: Drug: Abemaciclib Tablet (Reference Formulation) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib
Measured: Baseline through Day 45
Secondary outcomes (1)
PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity [AUC(0-∞)]
Measured: Baseline through Day 45
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2026
- Study start2 Sep 2026
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07818967
- Sponsor's protocol ID
- 27817
- Other IDs
- I3Y-MC-JPEJ
- Status last verified
- Sep 2026
- First submitted
- 26 Aug 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open-Label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Abemaciclib (LY2835219) Test and Reference Formulations and an Alternate Administration Method, in Healthy Participants.
- ClinicalTrials.gov ID
- NCT07818967
- Acronym / sponsor ID
- 27817
- Conditions
- Healthy Volunteers
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 2 Sep 2026 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 14 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study is to compare different forms of abemaciclib (LY2835219) to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 12 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 10 days.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Abemaciclib (Test Formulation 1) | Experimental | Drug: Abemaciclib Tablet (Test Formulation)Administered orally in one of three treatment periods. |
| Abemaciclib (Test Formulation 2) | Experimental | Drug: Abemaciclib Oral Granules (Test Formulation)Administered orally in one of three treatment periods. |
| Abemaciclib (Reference Formulation 1) | Experimental | Drug: Abemaciclib Tablet (Reference Formulation)Administered orally in one of three treatment periods. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Have a body mass index (BMI) within the range of 18 to 32 kilograms per square meter (kg/m²), inclusive, and have a body weight of 45 kilograms (kg) or greater.
- Individuals assigned male at birth (AMAB) should be sterile, including vasectomy.
- Individuals who are assigned female at birth (AFAB) and are individuals not of childbearing potential (INOCBP).
- Have clinical laboratory test results within normal reference range for the population or investigative site.
Key exclusion criteria (19 listed)
- Have known allergies to abemaciclib, related compounds, or any components of the formulations, or have a history of significant atopy.
- Have a 12-lead electrocardiogram (ECG) abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis.
- Have abnormal blood pressure as determined by the investigator.
- Have a gastrointestinal disorder causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes.
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders that could significantly alter the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study medication, or of interfering with the interpretation of study data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Abemaciclib Tablet (Test Formulation)Administered orally as a tablet in one of three treatment periods. | Drug | Abemaciclib (Test Formulation 1) |
| Abemaciclib Tablet (Reference Formulation)Administered orally as a tablet in one of three treatment periods. | Drug | Abemaciclib (Reference Formulation 1) |
| Abemaciclib Oral Granules (Test Formulation)Administered orally in one of three treatment periods. | Drug | Abemaciclib (Test Formulation 2) |
Primary outcome
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib
Time frame: Baseline through Day 45
1 secondary outcome
PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity [AUC(0-∞)]
Time frame: Baseline through Day 45
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Volunteers
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Not yet recruitingObservational study
Screening Protocol
Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Abemaciclib Tablet (Test Formulation), Abemaciclib Tablet (Reference Formulation) and Abemaciclib Oral Granules (Test Formulation) in people with Healthy Volunteers, run by Eli Lilly and Company at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib (time frame: Baseline through Day 45). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.